© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Phenylbutazone first entered the pharmaceutical arena in the late 1940s, a time when the medical field was hungry for new approaches to pain and inflammation. This compound arrived as an answer for those seeking relief from the relentless grip of arthritis, especially before the era of modern non-steroidal anti-inflammatory drugs (NSAIDs). Its creators couldn’t have imagined the debates, regulations, bans, and comebacks that would follow. Decades ago, clinics and farms alike leaned heavily on phenylbutazone, turning to it as a straightforward, affordable solution. Laws around its use changed shape as reports piled up about side effects, yet the story didn’t end in withdrawal alone. Instead, researchers and regulators kept returning to its effectiveness and affordable price point, especially in veterinary contexts.
Phenylbutazone stands as a synthetic NSAID, used primarily to ease pain and swelling. Its main role rests in managing musculoskeletal disorders. You won’t find it prescribed much for people these days, since the safety record raised too many red flags. Animals—especially horses—get a different treatment, as it remains a key part of equine medicine. Tablets, pastes, and injectables fill the shelves of veterinary clinics. Some farmers still describe it as a “workhorse medicine,” given its track record and reliability in the right situation.
This compound takes the form of a white, crystalline powder, faintly bitter if you’re unfortunate enough to taste it. It dissolves a bit in alcohol, rarely budges in water, and melts somewhere above 100°C. The chemical structure includes two phenyl groups stuck to a central butazone core. This gives the molecule its resilience against rapid breakdown, a key feature in soothing persistent inflammation. The molecular formula—C19H20N2O2—hardly changes across different commercial brands. Labs gauge its stability under various temperature and light conditions, since breakdown can influence both shelf life and safety.
Product labels carry heavy legal language these days, with regulators demanding clear dosing instructions and warnings about species-specific risks. Most veterinary versions restrict use to a narrow set of animals. Each label lists the concentration, mostly in grams per tablet or milliliter for liquids, along with proper storage instructions. Pharmacies fall under tight scrutiny, recording how much winds up in circulation. Some countries outlaw use in food-producing species entirely, in line with food safety standards. Batch numbers and expiry dates appear front and center, since mishandling or using expired stock can contribute to accidental poisonings.
Synthesis usually starts with hydrazine acting on diketone precursors. The process calls for careful handling, as both the raw materials and the final product create risk for untrained handlers. The operation runs at controlled temperatures, helping avoid runaway reactions. Industrial plants set up containment protocols to keep spills in check, especially given the environmental impact of leftover solvents and byproducts. Technicians keep testing samples along the way, checking purity and yield at every turn. Over the years, improvements have helped cut down on hazardous waste.
In solution, phenylbutazone can degrade if exposed to excess heat or strong acids. Chemists have spent years tweaking the molecule’s backbone to squeeze out less toxic analogs or extend its half-life in certain animals. By adding or swapping functional groups, researchers hoped for gentler side effect profiles. Some changes delivered compounds with faster onset or fewer gastrointestinal complications. Each step forward has meant rounds of animal testing and, for human products, multiple clinical trials. The field of veterinary pharmacology keeps looking for ways to blend the pain relief of phenylbutazone with the safety records of newer drugs.
Ask around, and you’ll hear phenylbutazone called by dozens of names. Some old-timers remember it as “Butazolidin,” the name on the original bottles. Vets sometimes call it just “bute,” a quick shorthand in the barn. Across the globe, pharmaceutical companies turn out local versions under many different trade names, with only subtle differences in fillers or packaging. The variety in names has led to confusion, especially when importers cross borders without clear documentation. Pharmacies rely on up-to-date databases to distinguish formulations, especially since some generics cut costs by swapping non-active ingredients.
Phenylbutazone’s reputation swings wildly depending on the setting. Decades of research point to a risk of blood disorders, kidney strain, and liver inflammation, especially in humans. The World Health Organization, the FDA, and their equivalents in Europe all draw firm lines: this is not a game for amateurs. Hospitals once kept it in the formulary but pulled it after high-profile fatalities linked to aplastic anemia. Veterinary operators wear gloves, store the powder away from food, and document every administration. Farms using “bute” keep logs to show they aren’t dosing cattle or dairy cows bound for human consumption. Farms and clinics with tight protocols avoid most mishaps, but the margin for error stays slim.
You’ll find phenylbutazone crossing between medical and animal worlds with very clear rules on both sides. In the equine arena, the drug controls lameness, arthritis pain, and post-surgical inflammation. Owners sometimes swear by it for stall-bound horses recovering from tough injuries. Some small animal practices still pull out the medication, but the risks usually outweigh the benefits in dogs and cats; alternative NSAIDs usually win out. Human use in most regions now only pops up in rare, desperate cases, if at all. Regulatory agencies stress that its presence in meat or milk destined for human tables is unacceptable, so surveillance programs test produce for traces of it.
Modern labs still look at phenylbutazone as a starting point in drug design. Medicinal chemists see it as an old friend, full of lessons on how structure can dictate power and risk. Some try to engineer analogs with better safety records. Others examine its mode of action, using it as a yardstick against which to measure new anti-inflammatories. Universities sometimes revisit it as a case study for drug repurposing, asking whether lower doses or different delivery methods could trim the hazard curve. Pressures from animal welfare groups keep the pace of research brisk, hoping for options that do as much good with fewer side effects.
The main troubles come from the way phenylbutazone sticks around inside bodies, building up over repeated doses. In people, it links directly to bone marrow suppression and, less commonly, kidney or liver failure. Horses handle it better, but overdoses or long-term courses lead to gastrointestinal ulcers or even fatal colic. Regulatory agencies have published thousands of pages tracking cases, setting maximum residue levels, and demanding withdrawal periods before an animal enters the food chain. Toxicology teams run regular trials to understand species differences, so that mistakes shrink over time. Some studies track downstream ecological effects, especially since the compound can drift from barns into waterways.
As research advances, phenylbutazone looks set to remain a lesson more than a go-to treatment. Safer options for humans have pushed it out of most clinics, though it remains a mainstay in specific animal health sectors. Pharmaceutical companies profit from more refined NSAIDs, but basic pain control in working horses continues to drive demand for “bute.” Regulators may tighten monitoring even further, demanding updated risk evaluations and real-time reporting from large-scale animal operations. Cheaper, more transparent residue tests might empower smaller farms to follow best practices. The story keeps evolving, as science and society re-balance the scales between relief, risk, and responsibility.
Visit most barns or equestrian stables, and talk turns quickly to horses—legs, joints, soreness. Phenylbutazone, usually called “bute,” comes up a lot. It’s a non-steroidal anti-inflammatory drug (NSAID) that soothes pain and reduces swelling. In the world of veterinary medicine, especially with horses, it works a bit like ibuprofen does for people. Animals with lameness or arthritis often move better and hurt less after bute.
Equine athletes push their bodies hard. Racing, jumping, and dressage put stress on joints and tendons, which can lead to painful injuries or long-term conditions like osteoarthritis. Vets reach for phenylbutazone to take down the inflammation and relieve the pain. Every barn worker seems to keep tubes or tablets handy for horses coming up sore. I’ve seen old geldings and sprightly ponies both perk up after a treatment—eating better, walking without limping.
The medication often shows its best use after a tough workout or competition. Trainers give it to help horses recover, especially when natural rest feels too slow. I’ve known barns that rely on bute to keep aging lesson horses comfortable enough to earn their oats teaching new riders. Vets prescribe it because it’s affordable, effective, and easily given by mouth. A quick squirt of oral paste or tablets in the feed, and most horses don’t even notice.
Bute’s impact reaches beyond horses. This drug once helped people with arthritis, but its use in humans dropped after serious side effects popped up. Studies link it to stomach ulcers, kidney trouble, and bone marrow issues. Because of this, doctors in most countries avoid prescribing phenylbutazone for people now.
In the horse world, the drug comes with its own set of rules and red tape. Race tracks and competition organizers often ban bute before events. The goal is to keep play fair and protect the animals. Horses running on painkillers could mask injuries and end up with worse long-term damage. Regulators perform drug tests at major horse shows and races. Trainers caught giving bute too close to a race face steep fines or suspension.
Phenylbutazone gives horses a way to stay active and pain-free, but it doesn’t replace good care. The temptation to lean on it for a quick fix runs high in competitive environments. Years around barns taught me that real animal wellness means more than masking pain. It demands careful attention to how much bute animals get, for how long, and for what reason. Vets watch for signs of ulcers or kidney strain and suggest safer alternatives when possible.
Other NSAIDs, improved diagnostics, and softer riding surfaces can lower the damage that leads owners to reach for bute. Some stables swap regular injections, hydrotherapy, or changes in feeding so horses rely less on drugs. Educating owners and trainers remains key. Anyone using phenylbutazone must know both its power and its risks, prioritizing the long-term soundness and well-being of their animals.
Phenylbutazone shows up a lot in horse barns and sometimes for treating dogs, but you don’t see it prescribed for people in the United States anymore. Vets lean on this drug to fight pain and swelling, much like ibuprofen for animals. It delivers results, but nobody calls it gentle. The list of side effects runs longer than most people would like, so it helps to know what’s at stake before reaching for that tube.
The most common side effects hit the digestive system hardest. Horses and dogs can both wind up with stomach ulcers. I’ve seen a horse go off feed, showing classic signs: dull coat, slow movement, a sort of glazed-over look. Stomach pain in these animals doesn’t always look obvious. Runny manure or colic symptoms follow pretty fast. Vets report that anywhere from 20-30% of horses on phenylbutazone start to develop some sign of gut irritation.
Next, you see issues pop up in the kidneys. This drug forces kidneys to work overtime, especially if the animal isn’t drinking enough water. Blood tests sometimes catch this early. If the bloodwork shows spikes in creatinine and blood urea nitrogen, the kidneys are waving red flags. In the clinic, we measure water intake closely. A hot day, lots of sweating, or a horse laid up and not drinking can all make kidney shock much more likely.
One problem that catches a lot of owners and younger vets is swelling and fluid retention in the lower limbs. You might check the legs and find they’ve ballooned up overnight. Older horses and retired dogs seem especially prone, maybe because their bodies can’t shuffle excess salt and water around as efficiently.
Long-term use doesn’t leave the liver out of the picture. Liver enzymes climb as the organ tries to clear the drug from the system, and sometimes, the skin takes on a yellow tinge—classic jaundice. I’ve seen more than one blood panel light up after just a few weeks. In working horses who spend most of their lives on some pain-killing medication, liver stress stacks up over seasons.
Reducing these side effects starts with regular bloodwork. Many equine practices recommend baseline kidney and liver panels before starting the drug, followed by frequent follow-ups. Catching problems early gives you a shot at swapping to a safer option like firocoxib or meloxicam, which seem to trigger fewer gut problems.
Hydration matters more than most realize. Animals need access to fresh water all day. During heavy work or hot weather, watch for exhaustion and dehydration. Good hay and less grain help support stomach health, too.
Dosing low and stopping early always works better than trying to fix problems later. Stick close to veterinarian instructions. Most side effects linked to this drug come from giving too much or giving it too long.
Nobody should reach for phenylbutazone without a clear reason and a trusted veterinary guide. The drug works well for pain but always leaves a mark somewhere in the body. Paying attention to appetite, water consumption, and daily behavior flags most problems before they get bad. Check bloodwork often. If you see anything strange, ask the vet about changing course before it’s too late.
Phenylbutazone often shows up in farm talk, especially among horse owners and livestock handlers. Folks call it "bute" and rely on it to manage pain and swelling. Some people compare it to aspirin for animals, used to keep working horses comfortable and treat flare-ups in racing, polo, or at the track. Dogs have received it for pain in years past. Humans once saw it on prescriptions, too, for arthritis. But over time, doctors and regulators started sounding alarms about risks.
Nobody wants their horse lame or their dog hurting. Vets often reach for whatever eases suffering fast. Still, medicines aren’t without trade-offs. Phenylbutazone may ease pain and cut inflammation, but it can push liver and kidneys too far—especially with repeat use. Odds of stomach ulcers rise. “Bute” can cause bleeding in the digestive tract, sometimes mild, but on a bad day it turns serious.
People with hands-on experience know the warning signs. Horses off their feed or tucked up belly-wise might need a vet visit sooner rather than later. These are not one-off cases either. Research published in the Equine Veterinary Journal over the past decade has outlined thousands of horses with gastric trouble after extended bute doses—most under real-world field conditions, not just in carefully monitored labs. The risks stack up fastest if the horse is older or given more than one painkiller at a time. Personal experience and stories traded at barns confirm what the studies say.
Many still remember the European food scandals a decade ago when traces of bute showed up in meat supply chains. Phenylbutazone can cause a fatal blood disorder called aplastic anemia in humans, even at low levels. There’s no reliable test to prove a person will not react. Because of this, regulators in most countries banned its use in food animals like cattle, sheep, and goats. The World Health Organization and the FDA both cite human health as non-negotiable for food animal medication rules.
Still, keeping food safe is only one part of the puzzle. Backyard farmers and smallholders who retire horses to pasture sometimes send them down the food chain by accident, not thinking their old pain treatment lingers in muscle or fat.
Vets, trainers, and breeders all play a role. The more open conversations happen about side effects, the safer animals and people stay. Better tracking of medications in farm records can stop mistakes before they reach a slaughterhouse or packing plant. Owners who understand the dangers make wiser choices, especially during long-term care or hard-working seasons.
Large-scale studies, backed by people who handle animals every day, say that phenylbutazone works—in the short run. It’s not banned outright for horses or dogs, but vets need to keep watch, rotate drugs where possible, and talk honestly with owners about the risks. No one wants a suffering animal, but nobody needs one drug putting them at greater risk down the line.
Many in the field call for routine blood checks and tighter dose limits, plus clear communication between vets and owners. Modern NSAIDs like firocoxib and meloxicam often cost more, but sometimes, paying a few dollars extra beats rolling dice with old drugs. Careful disposal of unused bute keeps water supplies safer. Better labeling on meds helps barn hands and animal caretakers avoid mixing up treatments.
Most folks want to do right by their animals. Real progress starts with honest talk and real-world experience, not just instructions printed on a package.
Phenylbutazone, known in barns and vet clinics as “bute,” has played a huge role in easing pain and inflammation for horses with joint and soft-tissue problems. Its anti-inflammatory punch brings relief to animals that deal with arthritis, injury, or the aches and swelling that come from working hard. Dosing isn’t just scooping powder into a feed bucket; it runs deeper, involving animal safety, legal limits, and responsible vet oversight—something I’ve seen make all the difference in both backyard stables and professional barns.
For horses, the typical oral dosage lands at 2-4 milligrams per kilogram of body weight per day, often split into two doses. That means an average 500-kilogram adult horse gets one to two grams orally every twelve hours, or no more than four grams over a day. Injectable forms exist, but vets lean toward oral dosing because it lowers the risk of severe complications, such as tissue sloughing.
Phenylbutazone has no approved use in food-producing animals in many countries, including the United States, due to safety and residue concerns. Owners need to remember, no matter how tempting it feels to increase the amount for a sore animal, high doses or long-term use run up the risk for gastric ulcers, kidney trouble, or even bone marrow effects.
In practice, giving too much bute or for too long brings more problems than it solves. I have watched horses bounce back thanks to careful dosing—and I have also seen firsthand what happens when it gets pushed too far. Signs of trouble show up fast: colic, loss of appetite, swelling along the limbs, signs that the body’s filtering systems have taken a hit. Veterinary literature has plenty of case studies supporting these risks. The American Association of Equine Practitioners highlights that kidney damage and GI ulcers become much more likely above four grams per day or with prolonged use.
Every horse reacts differently. Some animals tolerate a standard dose for a week, but others show warning signs in just a few days. That experience means regular bloodwork and close monitoring are far from a luxury—they are part of responsible animal care.
Bute sits at the center of several controversies over illegal dosing in the racing world. Welfare issues and doping scandals rock sporting events when shortcuts get taken. That’s one reason regulators, such as the FEI and the United States Equestrian Federation, have set enforceable limits: no phenylbutazone allowed inside competition windows. These standards guide trainers, owners, and vets toward fair play and prioritize health.
The strongest solution has never come down to chasing relief through higher doses. Instead, open communication with veterinarians, regular rechecks, and honest conversations about comfort and quality of life reshape how owners turn to bute. Alternatives like targeted therapy, controlled exercise, and nutraceuticals join the fight, so horses do not rely solely on medication. Only by listening to what animals show in their recovery—and being unafraid to stop or taper medication—do horse people uphold the spirit of both good science and honest care.
Veterinarians use phenylbutazone, often just called “bute,” for relief of pain and inflammation in horses and sometimes in other animals. It was once a go-to option for people with arthritis before safety concerns pulled it mostly out of human use. Many folks working directly with animals attribute a smoother recovery and better quality of life to this medicine. Risks come with the territory, and a lot of that risk comes from less talked-about interactions with other drugs and underlying conditions.
Mixing medicines can set off problems, even if each one seems harmless alone. Phenylbutazone intensifies the effects of some drugs and makes others less effective. If a horse or dog already takes another NSAID—in the same family as ibuprofen or aspirin—you face a bigger chance of stomach ulcers or kidney trouble. I’ve seen horses on a bute and flunixin combo go from hardy to struggling with colic. The evidence backs it up: research published in the Journal of Veterinary Pharmacology describes gastric bleeding as a real risk when combining NSAIDs. Adding corticosteroids like dexamethasone ramps up the bleeding threat. It isn’t just theoretical—more than one stable has lost animals through gut bleeding linked to careless stacking of painkillers.
Bute gets cleared out by the liver, then the kidneys. Animals with injuries or bug-bitten and in pain don’t always show early signs of organ stress, especially cats and dogs. Any medicine that also uses these organs for processing—like certain antibiotics (gentamicin, for example) or chemotherapies—can compete for attention and gum up the works. There are many reports in veterinary literature tying chronic bute use to kidney failure, especially under dehydration or stress. Hydration and nutrition matter, and so does knowing every pill that crosses your animal’s lips.
Phenylbutazone moves through the food chain. People don’t forget the scare over horsemeat found in beef products in Europe, especially after learning bute traces turned up in some tested samples. Because it lingers in animal tissues, regulatory agencies set strict withdrawal times and ban its use in food animals. For the folks who handle these animals—farm workers, trainers, even pet owners—contact brings risk, too. Accidental exposure, even in small amounts, can cause blood cell problems (like aplastic anemia), and the World Health Organization flags those risks clearly.
Better education stands at the core of safe use. Veterinarians play a key role by asking about every supplement, prescription, or over-the-counter treatment in the barn’s medicine box. Keeping detailed records, paying attention to hydration and nutrition, and regular bloodwork all help spot trouble before it starts. Avoiding drug combinations that target the same organs lowers risk. For animals with kidney or liver issues, pain relief plans demand extra care—sometimes pivoting to drugs with a cleaner safety profile like firocoxib or meloxicam. Full communication between owners, trainers, and veterinarians sets everyone up for fewer heartbreaking mistakes.
Balancing pain relief and safety shapes every decision in animal medicine. The reality of phenylbutazone’s drug interactions reminds us that quick relief can carry a high cost. Trusting science, thoughtful protocols, and honest conversation keeps both animals and humans out of harm’s way.
| Names | |
| Preferred IUPAC name | 4-butyl-1,2-diphenylpyrazolidine-3,5-dione |
| Other names |
Butazolidin Bute Phenylbutazolidine |
| Pronunciation | /fɛˌnɪl.bjuːˈtæz.oʊn/ |
| Identifiers | |
| CAS Number | 50-33-9 |
| Beilstein Reference | 1207932 |
| ChEBI | CHEBI:8063 |
| ChEMBL | CHEMBL1439 |
| ChemSpider | 9670 |
| DrugBank | DB00621 |
| ECHA InfoCard | 100.004.641 |
| EC Number | 200-024-1 |
| Gmelin Reference | 73108 |
| KEGG | C07415 |
| MeSH | D010634 |
| PubChem CID | 4921 |
| RTECS number | DN6475000 |
| UNII | 8E49457OIY |
| UN number | UN2581 |
| Properties | |
| Chemical formula | C19H20N2O2 |
| Molar mass | 308.365 g/mol |
| Appearance | White or almost white, crystalline powder |
| Odor | Odorless |
| Density | 1.265 g/cm³ |
| Solubility in water | slightly soluble |
| log P | 4.1 |
| Vapor pressure | 4.38E-09 mmHg |
| Acidity (pKa) | 4.5 |
| Basicity (pKb) | 13.10 |
| Magnetic susceptibility (χ) | -70.0E-6 cm³/mol |
| Refractive index (nD) | 1.645 |
| Viscosity | Viscosity: 150 - 250 cP |
| Dipole moment | 3.0457 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 385.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -108.8 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -4706 kJ·mol⁻¹ |
| Pharmacology | |
| ATC code | M01AA01 |
| Hazards | |
| Main hazards | May cause cancer, causes damage to organs through prolonged or repeated exposure, harmful if swallowed, causes serious eye irritation. |
| GHS labelling | GHS07, GHS08 |
| Pictograms | GHS05,GHS07,GHS08 |
| Signal word | Warning |
| Hazard statements | H302 + H332: Harmful if swallowed or if inhaled. |
| Precautionary statements | P264, P270, P280, P301+P312, P304+P340, P305+P351+P338, P308+P313, P405, P501 |
| NFPA 704 (fire diamond) | 2-3-0 |
| Flash point | 86°C |
| Autoignition temperature | 490°C |
| Lethal dose or concentration | LD50 (oral, rat): 660 mg/kg |
| LD50 (median dose) | Oral-rat LD50: 660 mg/kg |
| NIOSH | SN 4550000 |
| PEL (Permissible) | PEL: 2 mg/m³ |
| REL (Recommended) | 5-6 mg/kg |
| IDLH (Immediate danger) | 200 mg/m3 |
| Related compounds | |
| Related compounds |
Benzbromarone Bumadizone Clopirac Feprazone Ketophenylbutazone Mofebutazone Oxyphenbutazone Propyphenazone Suprofen |
